NovoCure Limited
NVCR
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesotheā¦ read more
Healthcare
Medical Instruments & Supplies
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$18.05
Price-0.28%
-$0.05
1Y
Price
Market Cap
$2.091b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-36.4%
EBITDA Margin-40.9%
Net Profit Margin-10.7%
Free Cash Flow Margin-36.4%
EBITDA Margin-40.9%
Net Profit Margin-10.7%
Free Cash Flow MarginRevenue
$674.414m
+2.9%
1y CAGR+10.0%
3y CAGR+6.2%
5y CAGREarnings
-$173.046m
-27.0%
1y CAGR+3.6%
3y CAGR-28.3%
5y CAGREPS
-$1.53
-25.4%
1y CAGR+5.5%
3y CAGR-26.3%
5y CAGRBook Value
$330.717m
$787.926m
Assets$457.209m
Liabilities$234.940m
DebtDebt to Assets
29.8%
-1.5x
Debt to EBITDAFree Cash Flow
-$48.072m
+36.5%
1y CAGR+19.4%
3y CAGR-276.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company